Vanda Pharmaceuticals Inc. (VNDA)
Market Performance – 24 Hours (Ending 05:53 PM CET, Thursday 22 Oct 2026)
- Closing price: USD 4.07
- Daily change: ‑3.84 %
- Current share supply: 60.5 million
- Market capitalization: USD 252.1 million
- Volume traded in last 24 hours: USD 4.4 million
- Monthly change (since last month end): ‑23.03 %
- 200‑day simple moving average: USD 6.34
- 52‑week high: USD 9.94 (03 Oct 2026)
- 52‑week low: USD 3.97 (21 Oct 2026)
Upcoming Corporate Disclosure
- Event: Publication of third‑quarter 2026 financial results.
- Date: After market close, Wednesday 28 Oct 2026.
- Conference Call: 4:30 PM ET on 28 Oct 2026.
- Call will be webcast and recorded on Vanda’s website.
- Replay available until 4 Nov 2026.
- Focus: Review of financial performance and discussion of strategic initiatives.
- Contact: CFO information and additional resources provided in the press release.
- Corporate Positioning: Reiteration of Vanda’s role as a global biopharmaceutical firm developing therapies for unmet medical needs.
Peer Performance – Last 24 Hours
| Ticker | Company | Daily Change | Current Price (USD) | Market Capitalization (USD mn) | Additional Notes |
|---|---|---|---|---|---|
| OEC | Orion | –1.31 % | 5.32 | 301.8 | – |
| EGHT | 8x | –1.89 % | 2.10 | 300.4 | P/E = 67.83 |
| JENA | Jena Acquisition II | 0 % | 10.42 | 301.9 | – |
| MOBI | Mobia Medical | +6.64 % | 9.76 | 301.0 | – |
| NUAI | New Era Energy & Digital | +17.73 % | 2.81 | 300.5 | 4.4 % stake by KCM Capital Inc, AMC Fund, L.P., and Kent C. McCarthy (no voting/control). Former names: New Era Helium Inc., Roth CH V Holdings, Inc. Texas address listed. No other material changes. |
Company Overview
Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of clinical‑stage small‑molecule candidates for central nervous system disorders. The company’s portfolio includes a range of investigational therapies aimed at addressing unmet medical needs within its therapeutic area.
